美国 - 英文 - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - capecitabine 150 mg - - capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with dukes' c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine tablets are non-inferior to 5-fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine tablets in the adjuvant treatment of dukes' c colon cancer. - capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets instead of 5-fu/lv in combinations has not been adequately studied to

加拿大 - 英文 - Health Canada

dr reddy's laboratories ltd - gemcitabine (gemcitabine hydrochloride) - powder - 200mg - gemcitabine (gemcitabine hydrochloride) 200mg - antineoplastic agents

加拿大 - 英文 - Health Canada

dr reddy's laboratories ltd - gemcitabine (gemcitabine hydrochloride) - powder - 1g - gemcitabine (gemcitabine hydrochloride) 1g - antineoplastic agents

加拿大 - 英文 - Health Canada

dr reddy's laboratories ltd - gemcitabine (gemcitabine hydrochloride) - powder - 2g - gemcitabine (gemcitabine hydrochloride) 2g - antineoplastic agents

以色列 - 英文 - Ministry of Health

abic marketing ltd, israel - capecitabine - film coated tablets - capecitabine 150 mg - capecitabine - adjuvant colon cancer: capecitabine teva® is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: capecitabine teva® is indicated for the treatment of patients with advanced or metastatic colorectal cancer. advanced gastric cancer: capecitabine teva® is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. breast cancer combination therapy: capecitabine teva® in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: capecitabine teva® is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

以色列 - 英文 - Ministry of Health

abic marketing ltd, israel - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine teva® is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes stage c) colon cancer. colorectal cancer: capecitabine teva® is indicated for the treatment of patients with advanced or metastatic colorectal cancer. advanced gastric cancer: capecitabine teva® is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy. breast cancer combination therapy: capecitabine teva® in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: capecitabine teva® is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; iron oxide yellow; titanium dioxide; lactose; colloidal anhydrous silica; methylcellulose; iron oxide red; hyprolose; croscarmellose sodium; hypromellose; macrogol 8000 - colon cancer,capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; lactose; titanium dioxide; iron oxide yellow; macrogol 8000; croscarmellose sodium; hypromellose; magnesium stearate; colloidal anhydrous silica; methylcellulose; iron oxide red - colon cancer,capecitabine is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

美国 - 英文 - NLM (National Library of Medicine)

sagent pharmaceuticals - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine injection is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib), or metastatic (stage iv) non-small cell lung cancer. gemcitabine injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine injection is indicated for patients previously treated with 5-fu. gemcitabine injection is contraindicated in patients with a known hyperse

美国 - 英文 - NLM (National Library of Medicine)

northstar rx llc - gemcitabine hydrochloride (unii: u347pv74il) (gemcitabine - unii:b76n6sbz8r) - gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. gemcitabine for injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. gemcitabine for injection in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (stage iiia or iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc). gemcitabine for injection is indicated as first-line treatment for patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas. gemcitabine for injection is indicated for patients previously treated with fluorouracil. gemcitabine for injection is contraind